NDA 220605 is the FDA application for MIMRYLO (rusfertide). The FDA's Orange Book lists the applicant of record as TAKEDA PHARMACEUTICALS AMERICA INC and the first approval on it as Aug 28, 2026. Code name used in development: PTG-300. Owner today: Takeda Pharmaceutical Company Limited (NYSE: TAK).
Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 220605 · Orange Book NDA 220605
| Brand name (FDA) | MIMRYLO Orange Book trade name: MIMRYLO |
|---|---|
| Active ingredient (FDA) | RUSFERTIDE ACETATE |
| Code name | PTG-300 Source: Protagonist Therapeutics 10-K, Feb 28, 2022 “Our most advanced clinical asset, rusfertide (generic name for PTG-300), is an injectable hepcidin mimetic” |
| FDA applicant of record | TAKEDA PHARMACEUTICALS AMERICA INC FDA Orange Book data files as of Nov 13, 2026 |
|---|---|
| Owner today | Takeda Pharmaceutical Company Limited (TAK) Source: Takeda press release, Aug 28, 2026 “Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO” … “Takeda now has exclusive global development and commercialization rights for MIMRYLO.” |
| Earlier / partner | Protagonist Therapeutics (PTGX): licensed the drug to the current owner, Jan 31, 2024 Source: Takeda press release, Jan 31, 2024 “Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc., (Nasdaq: PTGX) today announced the signing” … “license and collaboration agreement for the development and commercialization of rusfertide” |
| No. | Trade name | Form; route | Strength | Approved |
|---|---|---|---|---|
| 001 | MIMRYLO | POWDER;SUBCUTANEOUS | EQ 9.5MG BASE/VIAL | Aug 28, 2026 |
| 002 | MIMRYLO | POWDER;SUBCUTANEOUS | EQ 19MG BASE/VIAL | Aug 28, 2026 |
| 003 | MIMRYLO | POWDER;SUBCUTANEOUS | EQ 28MG BASE/VIAL | Aug 28, 2026 |
| 004 | MIMRYLO | POWDER;SUBCUTANEOUS | EQ 41MG BASE/VIAL | Aug 28, 2026 |
| 005 | MIMRYLO | POWDER;SUBCUTANEOUS | EQ 54MG BASE/VIAL | Aug 28, 2026 |
Drug page: /drug/rusfertide
Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.